A. Allabi Et Al. , "Effects of CYP2C9*5,*6,*8 and *11 polymorphisms on losartan oxidation among black Africans," 8th World Congress of Clinical Pharmacology and Therapeutics , vol.31, Brisbane, Australia, 2004
Allabi, A. Et Al. 2004. Effects of CYP2C9*5,*6,*8 and *11 polymorphisms on losartan oxidation among black Africans. 8th World Congress of Clinical Pharmacology and Therapeutics , (Brisbane, Australia).
Allabi, A., Gala, J., Horsmans, Y., Babaoglu, M., Bozkurt, A., Heusterspreute, M., ... Yasar, U.(2004). Effects of CYP2C9*5,*6,*8 and *11 polymorphisms on losartan oxidation among black Africans . 8th World Congress of Clinical Pharmacology and Therapeutics, Brisbane, Australia
Allabi, AC Et Al. "Effects of CYP2C9*5,*6,*8 and *11 polymorphisms on losartan oxidation among black Africans," 8th World Congress of Clinical Pharmacology and Therapeutics, Brisbane, Australia, 2004
Allabi, AC Et Al. "Effects of CYP2C9*5,*6,*8 and *11 polymorphisms on losartan oxidation among black Africans." 8th World Congress of Clinical Pharmacology and Therapeutics , Brisbane, Australia, 2004
Allabi, A. Et Al. (2004) . "Effects of CYP2C9*5,*6,*8 and *11 polymorphisms on losartan oxidation among black Africans." 8th World Congress of Clinical Pharmacology and Therapeutics , Brisbane, Australia.
@conferencepaper{conferencepaper, author={AC Allabi Et Al. }, title={Effects of CYP2C9*5,*6,*8 and *11 polymorphisms on losartan oxidation among black Africans}, congress name={8th World Congress of Clinical Pharmacology and Therapeutics}, city={Brisbane}, country={Australia}, year={2004}}